Gram-negative bacillary meningitis.
The incidence of gram-negative bacillary meningitis has increased significantly in the past two decades. Approximately two thirds of all reported cases have occurred after neurosurgical procedures. With the development of the newer cephalosporins, the overall mortality rate has decreased from 40 to 80 per cent to 10 to 20 per cent.
D000617:Aminoglycosides / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D002511:Cephalosporins / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D002701:Chloramphenicol / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D006090:Gram-Negative Bacteria; D006801:Humans; D008581:Meningitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D010406:Penicillins / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D010406:Penicillins; D002701:Chloramphenicol; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole